Crisaborole 2% for Pediatric Periorificial Dermatitis: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study
Open Access
- 1 January 2026
- journal article
- Published by XMLink in Annals of Dermatology
- Vol. 38 (3) , 177-182
Abstract
Ollech A, et al. Ann Dermatol. 2026 Jun;38(3):177-182. https://doi.org/10.5021/ad.25.227Keywords
Funding Information
- Pfizer company (57944115)
This publication has 31 references indexed in Scilit:
- Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic DermatitisJAMA Dermatology, 2023
- Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical StudyAmerican Journal of Clinical Dermatology, 2023
- Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2022
- Topical calcineurin inhibitors for pediatric periorificial dermatitisJournal of the American Academy of Dermatology, 2020
- Phosphodiesterase 4 inhibitorsJournal of the American Academy of Dermatology, 2018
- Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitisJournal of the American Academy of Dermatology, 2017
- Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: A series of 15 casesJournal of the American Academy of Dermatology, 2017
- Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsJournal of the American Academy of Dermatology, 2016
- Perioral Dermatitis: A Review of the Condition with Special Attention to Treatment OptionsAmerican Journal of Clinical Dermatology, 2014
- Periorificial dermatitis in children and adolescentsJournal of the American Academy of Dermatology, 2006